Antiemetic Efficacy of Dexamethasone Omission in Antiemetic Therapy During Highly Emetogenic Chemotherapy for Breast Cancer
Die Pharmazie · 28.04.2026 · 81 (1-4)
DOI: 10.31083/pharmazie51804 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Die Pharmazie, online erschienen am 28.04.2026. Verfasst von Wataru Suzuki und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 135-8550 Tokyo, Japan. Hauptthemen laut MEDLINE: Antiemetics, Dexamethasone, Breast Neoplasms, Vomiting. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Dexamethasone is typically included in the anti-emetic regimens during the administration of anticancer drugs. However, the incidence and severity of nausea and vomiting in patients receiving anticancer therapy, for whom dexamethasone must be avoided to prevent the recurrence of diabetes mellitus or hepatitis, remain unknown.
Methods
This retrospective, observational study evaluated nausea and vomiting in patients with breast cancer who underwent highly emetogenic chemotherapy, including anthracycline and cyclophosphamide, for breast cancer. In all patients, dexamethasone was completely omitted from the standard antiemetic regimen for reasons such as hepatitis, and only palonosetron and aprepitant were administered.
Results
For the 82 evaluated cases, the incidence of nausea was 84.1%, vomiting was 14.6%, and the complete response (CR) rate was 8.5%. In addition, the incidence rate of grade 2 or higher nausea (CTCAE ver. 4) was 47.6%, and the proportion of cases in which anticancer drug doses were reduced in the subsequent course due to nausea and vomiting was 2.4%. Factor analysis showed that treatment regimens, age, drinking history, history of prior chemotherapy, and reasons for omitting dexamethasone had no significant effects on the incidence of chemotherapy-induced nausea and vomiting.
Conclusions
This study confirmed that the antiemetic effect of only administering palonosetron and aprepitant is insufficient for patients receiving highly emetogenic chemotherapy in whom dexamethasone cannot be administered. Prophylactic administration of other antiemetic drugs is necessary to effectively manage nausea and vomiting in patients receiving anticancer therapy who cannot receive dexamethasone.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 135-8550 Tokyo, Japan.
- Department of Clinical Pharmacology, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 192-0392 Tokyo, Japan.
- Department of Breast Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 135-8550 Tokyo, Japan.
Zitieren
APA
Suzuki, W., Suzuki, K., Yokokawa, T., Kobayashi, K., Aoyama, T., Sugisaki, T., Shibata, N., Hatori, M., Kawakami, K., Takano, T., & Yamaguchi, M. (2026). Antiemetic Efficacy of Dexamethasone Omission in Antiemetic Therapy During Highly Emetogenic Chemotherapy for Breast Cancer. Die Pharmazie, 81(1-4). https://doi.org/10.31083/pharmazie51804
Vancouver
Suzuki W, Suzuki K, Yokokawa T, Kobayashi K, Aoyama T, Sugisaki T, et al. Antiemetic Efficacy of Dexamethasone Omission in Antiemetic Therapy During Highly Emetogenic Chemotherapy for Breast Cancer. Die Pharmazie. 2026;81(1-4). doi:10.31083/pharmazie51804
BibTeX
@article{Suzuki2026,
author = {Suzuki, Wataru and Suzuki, Kenichi and Yokokawa, Takashi and Kobayashi, Kazuo and Aoyama, Takeshi and Sugisaki, Takahito and Shibata, Naoki and Hatori, Masahiro and Kawakami, Kazuyoshi and Takano, Toshimi and Yamaguchi, Masakazu},
title = {Antiemetic Efficacy of Dexamethasone Omission in Antiemetic Therapy During Highly Emetogenic Chemotherapy for Breast Cancer},
journal = {Die Pharmazie},
year = {2026},
volume = {81},
number = {1-4},
doi = {10.31083/pharmazie51804}
}
EUVIMED